Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.
Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.
复制标题
DOI：
10.1080/14760584.2016.1194759
复制
发表时间：
2016-12
影响因子：
6.2
通讯作者：
Baumert TF
中科院分区：
文献类型：
--
作者：
Fauvelle C;Colpitts CC;Keck ZY;Pierce BG;Foung SK;Baumert TF
有超过 1.5 亿慢性感染者，丙型肝炎病毒 (HCV) 仍然是全球巨大的健康负担。直接作用的抗病毒药物极大地改善了病毒的治愈效果。然而，治疗的机会有限、感染的晚期检测和治愈后的再感染表明需要一种疫苗来全球控制感染。诱导中和抗体 (nAb) 的疫苗已被证明可以成功预防多种病毒感染，目前正在针对 HCV 进行开发。在此，我们回顾了旨在通过诱导广泛的 nAb 来预防慢性 HCV 感染的疫苗开发进展。对感染患者病毒免疫逃避的了解、新型模型系统的开发以及病毒包膜糖蛋白 E2 的最新结构特征，显着推进了我们对病毒中和分子机制的理解，同时开发了几种候选疫苗。虽然 HCV 疫苗的开发仍然面临病毒高度多样性和免疫逃避的挑战，但 HCV 研究的显着进展推动了疫苗的开发。几种候选疫苗已在动物模型和人类中表现出强烈的 nAb 诱导作用。下一步将进行随机临床试验，以评估其预防慢性感染的临床功效。
With more than 150 million chronically infected people, hepatitis C virus (HCV) remains a substantial global health burden. Direct-acting antivirals have dramatically improved viral cure. However, limited access to therapy, late stage detection of infection and re-infection following cure illustrate the need for a vaccine for global control of infection. Vaccines with induction of neutralizing antibodies (nAbs) have been shown to protect successfully against infections by multiple viruses and are currently developed for HCV. Here we review the progress towards the development of vaccines aiming to confer protection against chronic HCV infection by inducing broadly nAbs. The understanding or viral immune evasion in infected patients, the development of novel model systems and the recent structural characterization of viral envelope glycoprotein E2 has markedly advanced our understanding of the molecular mechanisms of virus neutralization with the concomitant development of several vaccine candidates. While HCV vaccine development remains challenged by the high viral diversity and immune evasion, marked progress in HCV research has advanced vaccine development. Several vaccine candidates have shown robust induction of nAbs in animal models and humans. Randomized clinical trials are the next step to assess their clinical efficacy for protection against chronic infection.
登录
查看更多内容
DOI：
10.1084/jem.20090766
发表时间：
2010-08-30
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Fafi-Kremer S;Fofana I;Soulier E;Carolla P;Meuleman P;Leroux-Roels G;Patel AH;Cosset FL;Pessaux P;Doffoël M;Wolf P;Stoll-Keller F;Baumert TF
通讯作者：
Baumert TF
影响因子：
5.4
作者：
Alexander, Jason;Wong, Ji-Xhin;Houghton, Michael
通讯作者：
Houghton, Michael
影响因子：
29.4
作者：
Dowd KA;Netski DM;Wang XH;Cox AL;Ray SC
通讯作者：
Ray SC
人类单克隆抗体MBL-HCV1延迟肝移植后HCV病毒反弹：一项随机对照研究。
DOI：
10.1111/ajt.12083
发表时间：
2013-04
期刊：
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子：
--
作者：
Chung RT;Gordon FD;Curry MP;Schiano TD;Emre S;Corey K;Markmann JF;Hertl M;Pomposelli JJ;Pomfret EA;Florman S;Schilsky M;Broering TJ;Finberg RW;Szabo G;Zamore PD;Khettry U;Babcock GJ;Ambrosino DM;Leav B;Leney M;Smith HL;Molrine DC
通讯作者：
Molrine DC
影响因子：
14.9
作者：
Bohne-Lang A;von der Lieth CW
通讯作者：
von der Lieth CW